What are Treatments for Blastic Plasmacytoid Dendritic Cell Neoplasm?

Due to the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the lack of randomized clinical trials, there is no standard treatment for BPDCN. However, several treatment options have been explored, including chemotherapy, stem cell transplantation, and targeted therapy. The choice of treatment depends on the patient's overall health, age, and disease stage.

1. Chemotherapy

Chemotherapy is often the first line of treatment for BPDCN. It involves the use of drugs to kill cancer cells or stop them from growing. The most commonly used chemotherapy regimen for BPDCN is called CHOP, which includes the drugs cyclophosphamide, doxorubicin, vincristine, and prednisone. Another regimen, known as hyper-CVAD, includes cyclophosphamide, vincristine, doxorubicin, and dexamethasone. These regimens can be effective in controlling the disease, but they are often associated with significant side effects and the risk of relapse is high.

2. Stem Cell Transplantation

Stem cell transplantation, specifically allogeneic hematopoietic stem cell transplantation (allo-HSCT), is considered the most effective treatment for BPDCN, especially for patients in first remission. This procedure involves replacing the patient's diseased bone marrow with healthy stem cells from a donor. However, this treatment is associated with significant risks, including graft-versus-host disease and infection, and is typically reserved for younger patients with good performance status.

3. Targeted Therapy

Targeted therapy is a newer treatment option for BPDCN. This approach involves the use of drugs that specifically target cancer cells, sparing healthy cells and reducing side effects. The first targeted therapy approved for BPDCN is tagraxofusp (Elzonris), a CD123-directed cytotoxin. This drug works by binding to CD123, a protein that is overexpressed on BPDCN cells, and delivering a toxin that kills the cells. Other targeted therapies, such as venetoclax (a BCL-2 inhibitor) and SL-401 (a diphtheria toxin conjugate), are currently being investigated in clinical trials.

4. Clinical Trials

Clinical trials can provide access to cutting-edge treatments that are not yet approved but show promise over years of testing. The choice of a clinical trial depends on a variety of factors including the patient's age, overall health and genetic changes in the BPDCN cells. It's important to discuss all treatment options, including goals and possible side effects, with your healthcare team to help make the best decision. 

To learn more about your BPDCN clinical trial options, visit HealthTree's BPDCN Clinical Trial Finder. Utilize the advanced filter option to locate trials that you are eligible to participate in. You can create a HealthTree account to favorite your top trial options so you can discuss them with your BPDCN specialist.

Want to Learn More About Blastic Plasmacytoid Dendritic Cell Neoplasm?

Keep reading HealthTree for Blastic Plasmacytoid Dendritic Cell Neoplasm's 101 pages!

• What Is Blastic Plasmacytoid Dendritic Cell Neoplasm?
• How Is Blastic Plasmacytoid Dendritic Cell Neoplasm Diagnosed?
• How Long Will I Live With Blastic Plasmacytoid Dendritic Cell Neoplasm?
• What Are The Signs And Symptoms Of Blastic Plasmacytoid Dendritic Cell Neoplasm?
• How Is Blastic Plasmacytoid Dendritic Cell Neoplasm Staged And Classified?